{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:21:34Z","timestamp":1774430494177,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jfo.2018.04.012","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T19:12:29Z","timestamp":1543000349000},"page":"945-954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-na\u00efve patients and patients intolerant to other hypotensive medications"],"prefix":"10.1016","volume":"41","author":[{"given":"S.","family":"Lazreg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Merad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Derdour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ghroud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kherroubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Meziane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Belkacem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Ouhadj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2018.04.012_bib0175","doi-asserted-by":"crossref","first-page":"6509809","DOI":"10.1155\/2016\/6509809","article-title":"Medical Management of Glaucoma in the 21st Century from a Canadian Perspective","volume":"2016","author":"Harasymowycz","year":"2016","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0180","first-page":"785","article-title":"Patient satisfaction with glaucoma therapy: reality or myth?","volume":"9","author":"Lemij","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0185","doi-asserted-by":"crossref","first-page":"518","DOI":"10.5301\/ejo.5000270","article-title":"Preservative-free treatment in glaucoma: who, when, and why","volume":"23","author":"Stalmans","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/jop.2008.0072","article-title":"The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence","volume":"25","author":"Zimmerman","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2018.04.012_bib0195","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","article-title":"Prevalence of ocular surface disease in glaucoma patients","volume":"17","author":"Leung EW1","year":"2008","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jfo.2018.04.012_bib0200","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","article-title":"Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications","volume":"29","author":"Fechtner","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2018.04.012_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","article-title":"Ocular surface disease and quality of life in patients with glaucoma","volume":"153","author":"Skalicky","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0210","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5301\/ejo.5000220","article-title":"Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients","volume":"23","author":"Rossi","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5301\/ejo.5000181","article-title":"Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension","volume":"23","author":"Baudouin","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1542-0124(12)70120-9","article-title":"Effects of topical antiglaucoma medications on the ocular surface","volume":"3","author":"Asbell","year":"2005","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2018.04.012_bib0225","first-page":"155","article-title":"Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany","volume":"6","author":"Thelen","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1874364101408010067","article-title":"Ocular surface alterations and topical antiglaucomatous therapy: a review","volume":"8","author":"Actis","year":"2014","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.jfo.2018.04.012_bib0235","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","article-title":"Chapter 3: Treatment principles and options. Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options","volume":"101","author":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0240","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14656566.2012.662219","article-title":"A review of the use of latanoprost for glaucoma since its launch","volume":"13","author":"Digiuni","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jfo.2018.04.012_bib0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14740338.6.1.45","article-title":"The side effects of the prostaglandin analogues","volume":"6","author":"Hollo","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jfo.2018.04.012_bib0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2018.04.012_bib0255","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2147\/OPTH.S76053","article-title":"The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies","volume":"8","author":"Radcliffe","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0260","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0002-9394(00)00527-4","article-title":"Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study","volume":"130","author":"Piltz","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0265","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jfo.2018.04.012_bib0270","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0275","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ceo.12431","article-title":"Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease","volume":"43","author":"Goldberg","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0280","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bjo.85.8.983","article-title":"Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension","volume":"85","author":"Zhang","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0285","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00417-002-0462-2","article-title":"Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops","volume":"240","author":"Korte","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0290","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1177\/0091270011420254","article-title":"Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma","volume":"52","author":"Quaranta","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0295","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5301\/ejo.5000006","article-title":"Timogel\u00ae vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance","volume":"22","author":"Rolle","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0300","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jfo.2011.03.012","article-title":"Plasma levels and systemic safety of 0.1% unpreserved timolol maleate gel, 0.5% timolol aqueous solution and 0.5% timolol maleate gel","volume":"35","author":"Bonnin","year":"2012","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0305","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1167\/iovs.04-1331","article-title":"In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells","volume":"46","author":"Guenoun","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2018.04.012_bib0310","first-page":"40","article-title":"In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis)","volume":"110","author":"Baudouin","year":"2012","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jfo.2018.04.012_bib0315","doi-asserted-by":"crossref","first-page":"e33913","DOI":"10.1371\/journal.pone.0033913","article-title":"Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jfo.2018.04.012_bib0320","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1111\/aos.12261","article-title":"In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma","volume":"92","author":"Frezzotti","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0325","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jfo.2012.04.015","article-title":"Safety and efficacy of unpreserved timolol 0.1% gel in patients controlled by preserved latanoprost with signs of ocular intolerance","volume":"36","author":"Delval","year":"2013","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0330","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1089\/jop.2013.0216","article-title":"Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers","volume":"30","author":"Iester","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2018.04.012_bib0335","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/OPTH.S126042","article-title":"Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction","volume":"11","author":"Mu\u00f1oz Negrete","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2018.04.012_bib0340","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/OPTH.S143287","article-title":"Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction","volume":"11","author":"Beck","year":"2017","journal-title":"Clin Ophthalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551218304303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551218304303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:08:46Z","timestamp":1759259326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551218304303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0181551218304303"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2018.04.012","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-na\u00efve patients and patients intolerant to other hypotensive medications","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2018.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}